Asthma and the beta agonist debate.
作者信息
Crane J, Pearce N, Burgess C, Beasley R
机构信息
Wellington Asthma Research Group, Wellington School of Medicine, New Zealand.
出版信息
Thorax. 1995 Sep;50 Suppl 1(Suppl 1):S5-10. doi: 10.1136/thx.50.suppl_1.s5.
Abstract
摘要
相似文献
1
Asthma and the beta agonist debate.哮喘与β受体激动剂之争
Thorax. 1995 Sep;50 Suppl 1(Suppl 1):S5-10. doi: 10.1136/thx.50.suppl_1.s5.
2
Epidemiologic studies of beta agonists and asthma deaths.
Epidemiol Rev. 1998;20(2):173-86. doi: 10.1093/oxfordjournals.epirev.a017979.
3
Re: "Confounding by indication and channeling over time: the risks of beta2-agonists".关于：“随时间推移的指征性混杂和渠道效应：β2 激动剂的风险”。
Am J Epidemiol. 1997 Nov 15;146(10):885-7. doi: 10.1093/oxfordjournals.aje.a009210.
4
Asthma deaths in New Zealand: whodunnit?
Lancet. 1995 Jan 7;345(8941):2-3. doi: 10.1016/s0140-6736(95)91143-x.
5
International trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970-1992.
J Clin Epidemiol. 1997 Mar;50(3):321-8. doi: 10.1016/s0895-4356(96)00375-7.
6
The use of beta agonists and the risk of death and near death from asthma.β受体激动剂的使用与哮喘导致的死亡及濒死风险。
J Clin Epidemiol. 2009 Jun;62(6):582-7. doi: 10.1016/j.jclinepi.2009.01.004.
7
Beta agonists and asthma mortality: déjà vu.β受体激动剂与哮喘死亡率：似曾相识。
Clin Exp Allergy. 1991 Jul;21(4):401-10. doi: 10.1111/j.1365-2222.1991.tb01679.x.
8
End of the New Zealand asthma mortality epidemic.
Lancet. 1995 Jan 7;345(8941):41-4. doi: 10.1016/s0140-6736(95)91159-6.
9
The saga of the New Zealand asthma mortality epidemic.
N Z Med J. 1995 Mar 8;108(995):91.
10
Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic.非诺特罗的停用与新西兰哮喘死亡率流行的终结。
Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):325-7. doi: 10.1159/000237016.
引用本文的文献
1
The Wiser Strategy of Using Beta-Agonists in Asthma: Mechanisms and Rationales.β-受体激动剂在哮喘治疗中的明智策略：作用机制与理论依据
Allergy Asthma Immunol Res. 2024 May;16(3):217-234. doi: 10.4168/aair.2024.16.3.217.
2
Bronchodilator treatment and deaths from asthma: case-control study.支气管扩张剂治疗与哮喘死亡：病例对照研究
BMJ. 2005 Jan 15;330(7483):117. doi: 10.1136/bmj.38316.729907.8F. Epub 2004 Dec 23.
3
Mortality of adults with asthma: a prospective cohort study.成年哮喘患者的死亡率：一项前瞻性队列研究。
Thorax. 1997 Jan;52(1):49-54. doi: 10.1136/thx.52.1.49.
本文引用的文献
1
DANGEROUS EFFECTS OF ISOPRENALINE IN MYOCARDIAL FAILURE.异丙肾上腺素在心肌衰竭中的危险作用。
Lancet. 1965 Jul 17;2(7403):104-6. doi: 10.1016/s0140-6736(65)92221-x.
2
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.哮喘患者超额死亡率及吸入性β受体激动剂使用情况的队列分析。
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):604-10. doi: 10.1164/ajrccm.149.3.8118625.
3
4
Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?吸入性β-受体激动剂的使用与因严重程度混淆导致的危及生命的哮喘之间是否存在关联？
Am Rev Respir Dis. 1993 Jul;148(1):75-9. doi: 10.1164/ajrccm/148.1.75.
5
The myocardial effects of fenoterol, isoprenaline and salbutamol in normoxic and hypoxic sheep.非诺特罗、异丙肾上腺素和沙丁胺醇对常氧和低氧绵羊的心肌效应。
Int J Exp Pathol. 1994 Oct;75(5):357-62.
6
Confounding by severity does not explain the association between fenoterol and asthma death.病情严重程度导致的混杂因素并不能解释非诺特罗与哮喘死亡之间的关联。
Clin Exp Allergy. 1994 Jul;24(7):660-8. doi: 10.1111/j.1365-2222.1994.tb00970.x.
7
Use of beta 2 agonists in asthma: much ado about nothing? Still cause for concern.β2 激动剂在哮喘治疗中的应用：小题大做？仍值得关注。
BMJ. 1994 Sep 24;309(6957):794-5. doi: 10.1136/bmj.309.6957.794.
8
Regular vs as-needed inhaled salbutamol in asthma control.常规使用与按需使用吸入沙丁胺醇对哮喘控制的影响
Lancet. 1994 Jun 4;343(8910):1379-82. doi: 10.1016/s0140-6736(94)92520-8.
9
Beta-agonist use and death from asthma.β受体激动剂的使用与哮喘致死
JAMA. 1994 Mar 16;271(11):822-3.
10
End of the New Zealand asthma mortality epidemic.
Lancet. 1995 Jan 7;345(8941):41-4. doi: 10.1016/s0140-6736(95)91159-6.
Zotero 插件